98 related articles for article (PubMed ID: 1290297)
1. [Thromboxane A2 and prevention of cardiovascular diseases].
Schrör K
Z Kardiol; 1992; 81 Suppl 4():185-9. PubMed ID: 1290297
[TBL] [Abstract][Full Text] [Related]
2. [Thromboxane antagonism in thrombocytes--pathophysiology, pharmacology and possible clinical significance].
Schrör K
Wien Klin Wochenschr; 1991; 103(18):543-53. PubMed ID: 1836294
[TBL] [Abstract][Full Text] [Related]
3. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
4. Overview of physiological and pathophysiological effects of thromboxane A2.
Ogletree ML
Fed Proc; 1987 Jan; 46(1):133-8. PubMed ID: 2948837
[TBL] [Abstract][Full Text] [Related]
5. Thromboxane A2 in cardiovascular and renal disorders: is there a defined role for thromboxane receptor antagonists or thromboxane synthase inhibitors?
Smith EF
Eicosanoids; 1989; 2(4):199-212. PubMed ID: 2534279
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
[TBL] [Abstract][Full Text] [Related]
7. Defective signal transduction through the thromboxane A2 receptor in a patient with a mild bleeding disorder: deficiency of the inositol 1,4,5-triphosphate formation despite normal G-protein activation.
Mitsui T; Yokoyama S; Shimizu Y; Katsuura M; Akiba K; Hayasaka K
Thromb Haemost; 1997 May; 77(5):991-5. PubMed ID: 9184416
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
9. Acetyl glycerylphosphorylcholine aggregates human platelets through two distinct pathways, both dependent on arachidonic acid metabolism.
Macconi D; Morzenti G; Livio M; Morelli C; Cassina G; Remuzzi G
Lab Invest; 1985 Feb; 52(2):159-68. PubMed ID: 3155816
[TBL] [Abstract][Full Text] [Related]
10. Platelet and vascular smooth muscle thromboxane A2/prostaglandin H2 receptors.
Halushka PV; Mais DE; Saussy DL
Fed Proc; 1987 Jan; 46(1):149-53. PubMed ID: 2948839
[TBL] [Abstract][Full Text] [Related]
11. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review.
Fiddler GI; Lumley P
Circulation; 1990 Jan; 81(1 Suppl):I69-78; discussion I79-80. PubMed ID: 2136820
[TBL] [Abstract][Full Text] [Related]
12. Local anesthetic effects on TXA2 receptor mediated platelet aggregation using quenched flow aggregometry.
Honemann CW; Lo B; Erera JS; Polanowska-Grabowska R; Gear AR; Durieux M
Adv Exp Med Biol; 1999; 469():269-76. PubMed ID: 10667341
[No Abstract] [Full Text] [Related]
13. Castration reduces platelet thromboxane A2 receptor density and aggregability.
Ajayi AA; Halushka PV
QJM; 2005 May; 98(5):349-56. PubMed ID: 15820970
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiological actions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191.
Humphrey PP; Hallet P; Hornby EJ; Wallis CJ; Collington EW; Lumley P
Circulation; 1990 Jan; 81(1 Suppl):I42-52; discussion I59-60. PubMed ID: 2136817
[TBL] [Abstract][Full Text] [Related]
15. Thromboxane biosynthesis and antagonism in humans.
FitzGerald GA; Fitzgerald DJ; Lawson JA; Murray R
Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():199-203. PubMed ID: 2959047
[TBL] [Abstract][Full Text] [Related]
16. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion.
Hornby EJ; Foster MR; McCabe PJ; Stratton LE
Thromb Haemost; 1989 Jun; 61(3):429-36. PubMed ID: 2529661
[TBL] [Abstract][Full Text] [Related]
17. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacology of anti-platelet agents].
Lecompte T; Kher A; Gaillard JL; Samama M
J Mal Vasc; 1983; 8(1):3-16. PubMed ID: 6302191
[TBL] [Abstract][Full Text] [Related]
19. Biosynthesis and pharmacological modulation of thromboxane in humans.
Patrono C
Circulation; 1990 Jan; 81(1 Suppl):I12-5; discussion I22-3. PubMed ID: 2136814
[TBL] [Abstract][Full Text] [Related]
20. Pathogenetic analysis of five cases with a platelet disorder characterized by the absence of thromboxane A2 (TXA2)-induced platelet aggregation in spite of normal TXA2 binding activity.
Fuse I; Hattori A; Mito M; Higuchi W; Yahata K; Shibata A; Aizawa Y
Thromb Haemost; 1996 Dec; 76(6):1080-5. PubMed ID: 8972034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
